Nitric Oxide Synthase

Updated on 10-November-2019

spinqualitylabelsall models Neuronal nitric oxide synthase dimer complex with cofactor tetrahydrobiopterin, acetate and Zn+2 (grey), (PDB entry 2g6h) Show:Asymmetric Unit Biological Assembly Drag the structure with the mouse to rotate   Export Animated Image   Print3D Nitric Oxide Synthase (NOS) is an enzyme catalysing the formation of L-citrulline and nitric oxide (NO) from L-arginine. NOS is a homodimeric protein with 125- to 160-kDa per monomer. In mammals, NOS appears as 3 isozymes: neuronal NOS (nNOS) (for details see Nos1), cytokine-inducible NOS (iNOS) and endothelial NOS (eNOS). The N-terminal domain of NOS is an oxygenase domain (OD). NOS cofactors are: NADPH, FAD, FMN, heme and O2. See also Nos1. Introduction In mammals three isozymes of NOS have been identified: Neuronal NOS (nNOS), inducible NOS (iNOS), and endothelial NOS (eNOS). (The NOS enzymes are found in numeral organisms. Most facts used here are from the human NOS, but sites from different organisms are used). Neuronal NOS is producing NO in the nervous tissue in both the peripheral and the central nervous system. nNOS is functioning in cell signaling and communication - a vital part of the nervous tissue. Inducible NOS is connected with the immune system. Endothelial NOS is controlling the amount of NO signaling in the endothelial cells eg. blood vessel dilation. An overview of the structural organization of the NOS homodimer is given below. All cofactors are included and the electron transfer pathway which takes place in NOS is indicated. Each NOS monomer is composed of two domains: an N-terminal oxygenase domain and a C-terminal reductase domain. Each subunit is held together by a zinc ion, which is bound by two cysteines from each oxygenase domain. Calmodulin binds to a linker region between the two domains and is necessary for activity. The reductase domain supplies electrons for the NOS reaction which takes place in the oxygenase domain. The reductase domain contains two redox-active prosthetic groups, flavin adenine dinucleotide (FAD) and Flavin mononucleotide (FMN). Nicotinamide adenine dinucleotide phosphate(NADPH) binds to the domain and passes on an electron to FAD which passes the electron on to FMN. FMN passes the electron on to the heme in the oxygenase domain on the opposite subunit. The oxygenase domain contains 5,6,7,8-tetrahydrobiopterin (H4B) and the already mentioned heme. These two are also redox active groups. Besides Heme and H4B, the oxygenase domain binds the substrate L-arginine which takes part in the NO synthase reaction (see below). Many structures of NOS have been determined. A list with additional information can be seen here. The reaction of NOS As previously described NOS is an enzyme consisting of two domains; the N-terminal oxygenase domain and the C-terminal reductase domain. The NO production takes plase in the oxygenase domain, whereas the reductase domain provides the electrons necessary to drive the reaction in the oxygenase domain. The reaction is: thumb The reaction occurs in two steps. In the first step L-arginine is turned in to N-hydroxy-arginine. In the second step L-citrulline and NO are formed. The reaction utilizes 2O2 and 3 electrons from 3/2 NADPH. The Oxygenase domain of NOS The oxygenase domain contains the active site of the enzyme. The active site binds the substrate L-Arginine(Arginine) which is converted into citruline and NO (explained in details below). The domain has three cofactors bound: Tetrahydrobiopterin ((6R).5,6,7,8-Tetrahydrobiopterin) Heme (Heme) Zinc ion General Structure The oxygenase domain can be divided into three subdomains. Firstly, the substrate-binding subdomain, which is crescent in shape, binds the substrate in an interior pocket of the crescent. The Heme group is located between the tips of the crescent shape, thus closing the pocket in which the substrate is located. Secondly the H4B binding subdomain serves as a cap for the cavity created by the substrate binding domains crescent shape. Thirdly there is a subdomain consisting of a two helix bundle making up a hydrophobic core, however this subdomain is not thought to take part in the catalytic activity of the enzyme. Substrate binding The active site is highly conserved in the different NOS species. Thus it is possible to discuss substrate binding i general terms. The NOS enzyme binds its substrate (L-arginine) in the distal pocket by hydrogen bindings both to the guanidino[1] end and the amino acid end. Substrate in the catalytic site is shown in green with the heme and H4B shown. NOS binds its substrate by coordinating CO(or O2) to the heme at the site occupied by oxygen(it is the opposite site of the Cys coordination to heme - look in the 'heme' section). The binding of substrate leads to a 2-step transformation first to N-hydroxy-L-arginine (the tightly bound intermediate) and then NO and L-Citrulline. The product NO can then either diffuse out of the cavity or bind to the heme and function in NO auto-inhibition though this inhibition is diverse throughout the 3 isoforms. PDB structures used in the section above: 3nos, 2g6h H4B Structure of tetrahydrobiopterin H4B is an essential cofactor in NOS and in the aromatic amino acid hydroxylases. NOS contains two molecules of H4B, one in each monomer. The active site forms part of the cavity already described. This cavity can be visualized as a tunnel. Here H4B helps substrate interactions by lining the active-center tunnel and hydrogen bonding to the heme propionate and to alfa helix 7. The propionate group and alpha helix 7 are also involved in the L-Arg binding. This gives H4B the opportunity to play an important role in the control of subunit interactions and active site formation. H4B is therefore more or less a structural cofactor and has a stabilizing effect. Its structural importance is further reconned to play a role in dimer formation (dimerization requires bound zinc ion along with H4B), and major conformational changes leading to the formation of the active site channelform. Hydrogenbondings in H4B binding site (2nse) The H4B is bound by H-bonds to several of the residues surrounding it. For example is O4 of H4B H-bonded to Arg 367 and H4B N3 is H-bonded to one of the heme propionate groups ( the heme propionate group has two carboxylate oxygens in use for H-bonds). The overall picture of all the H-bonds can be seen by clicking on the figure on the left. But H4B is not only a structural cofactor, it also plays a very important role in NO synthesis, donating an electron to the heme. H4B can deliver an electron to the heme much faster than the reductase domain can, therefor H4B is used by NOS in the Arg hydroxylation, activating O2 by providing the second electron. Thus, H4B is a kinetically prefered electron donor. As shown in the reaction (bottom right, click for enlargement) the second electron, that H4B donates, helps the FeIIO2 intermediate to be reduced to oxidants that are able to react with Arg and N-hydroxy-L-arginine (NOHA) If H4B was not present the FeIIO2 intermediate would decay to superoxide and ferric enzyme due to the reductase domain being slower to deliver an electron than the proces of decay is to happen. H4B is faster than both of these processes. model for NOS oxygen activation PDB structures used in the section above: 3nos, 2g6h Heme Structure of Heme Heme is a prosthetic group containing an iron ion in the center of a large organic ring called porphyrin (See picture). The heme group can have several functions: it can act as a transporter of diatomic gases, as a chemical catalyst, detect diatomic gases, and take part in electron transfer. In NOS the heme both binds a diatomic molecule (CO, NO, O2) and functions in the multi electron pathway . As mentioned, the heme group takes part in the creation of the cavity running through the monomer. Arginine/citrulline diffuses in and out this cavity. The heme group in the cavity is held in place by van der Waals interactions with hydrophobic and aliphatic side chains of the protein making up the cavity. The propionic acid groups of heme forms several hydrogen bonds with water molecules inside the cavity. The iron in heme in pentacoordinated, with its axial ligand supplied by S of cysteine 186 (2nse) . Zinc In order for NOS to be active it has to dimerize and bind H4B. The dimer is structurally stabilized by a zinc ion. which is situated at the oxygenase domain interface of the dimer. The zinc ion is tetrahedrally coordinated by four cysteins (two from each monomer - Cys109 and Cys104). The zinc ion is found at a region which connects the N-terminal hook and the subunit core. The coordination of zinc arranges the N-terminal hooks so that they interact with their own subunit. However, when there is no zinc ion present, two of the thiolate ligands (cysteines) form a disulfide bond connecting the two subunits. PDB structures used in the section above: 2g6h The Reductase Domain of NOS The reductase domain of the NOS homodimer will not be discussed thoroughly on this page. However, a short discussion of the electron transfer which occurs will be given along with an introduction to the bound cofactors and the general structure. The reductase domain has three cofactors bound. NADPH(Nicotinamide adenine dinucleotide phosphate) FAD (Flavin adenine dinucleotide) FMN(Flavin mononucleotide) The reductase domain is, as mentioned, bound to the oxygenase domain by a linker region that binds calmodulin. The calmodulin linker consists of 32 residues. The binding of Ca2+ loaded calmodulin to the linker region is found to be crucial in that it induces a conformational change which is essential for electron transfer. The NOS activity is thereby dependent upon the Ca2+ concentration It is important to emphasize that the electron transfer occurs from the reductase domain of one subunit to the oxygenase domain of the opposite subunit (i.e. a trans transfer). The conformational change induced by calmodulin binding brings the mentioned reductase and oxygenase domains closer together, thus the linker acts as a hinge. The electron transfer occurs two times per NO molecule produced. The first transfer supplies an electron for the conversion of L-arginine to its intermediate, the second transfer for the conversion of the intermediate Citrulline and NO. In general the reductase domain can be divided into three subdomains: the NADPH binding domain, the FAD binding domain, and the FMN binding domain. The NADPH and FAD binding domains are associated whereas the FAD and FMN domains are connected by an α-helical binding domain. The electrons donated by NADPH is passed on to FAD. FAD then shuttles the electron to FMN. The FMN binding domain is a flexible domain and here the conformational change occurs. The binding of calmodulin rotates the reductase domain and oxygenase domain along a vertical axis, thus bringing the reductase domain closer to the opposite oxygenase domain. The electron can then due to shorter distance be passed on the the heme group of the oxygenase domain . The iron ion in the heme group is reduces from iron (III) to iron (II) which catalyses the substrate reaction. Structures used in the section above: 1tll 3D Structures of Nitric Oxide Synthase Nitric Oxide Synthase 3D structures

3D Structures of Nitric Oxide Synthase

{"openlevels":0}

• Endothelial NOS
  • Nos1 – h-eNOS OD - human
    
  • Nos1, here – h-eNOS OD+arginine
    
  • 3nos – h-eNOS OD+chlorzoxazone
    
  • 2g6h, aromatic amino acid hydroxylases, 2nse, 3nos, 2g6h, Heme, prosthetic group, porphyrin, 2nse, 2g6h, 1tll, Nitric Oxide Synthase 3D structures, 6nh2, 6nh1, 6cif, 6cie – h-eNOS OD+ inhibitor
    
  • 1nsi - h-eNOS OD+ Zn
    
  • 3nld, 3nle, 3nlf, 3nlg, 3jww, 3jwx, 3jwy, 3jwz, 3dqs, 3dqt, 3pnh, 4luw – b-eNOS OD+pyrrolidinomethyl pyridine derivative – bovine
    
  • 1dm6 – b-eNOS OD+guanidine derivative
    
  • 3nlh, 3rqo, 3rqp – b-eNOS OD (mutant)+pyrrolidinomethyl aminopyridine derivative
    
  • 1rs8, 1rs9, 1p6n – b-eNOS OD +dipeptide inhibitor
    
  • 1nse – b-eNOS OD
    
  • 1p6n – b-eNOS OD +dipeptide inhibitor
    
  • 5nse, 1fol, 1foo, 1fop, 1dm7, 2nse, 3nse, 4nse – b-eNOS OD+arginine derivative
    
  • 6nse – b-eNOS OD+canavanine
    
  • 7nse – b-eNOS OD+ADMA
    
  • 1i83, 1d1v, 1d1x, 1d1y, 1ed4, 9nse – b-eNOS OD+urea derivative
    
  • 1dmj, 1dmk – b-eNOS OD+pterin derivative
    
  • 1foi, 1dmi, 1i83, 3n5p, 3n5q, 3n5r, 3n5s, 3n5t, 3n5v, 3n5w, 3n5x, 3n5y, 3n5z, 3n60, 3n61, 3n62, 3n63, 3n64, 3n65, 3n66, 3n67, 3n68, 3n69, 3n6a, 3n6b, 3n6c, 3n6d, 3n6e, 3n6f, 3n6g, 3nlt, 3nlu, 3e7s, 5vv6, 5vv7, 5vv8, 5vv9, 4upq, 4upr, 4ups, 4upt, 5vva, 5vvb, 5vvc, 5vvd, 5vvg, 5vvn, 5uo8, 5uo9, 5uoa, 5uob, 5uoc, 5uod, 5fvy, 5fvz, 5fj2, 5fj3, 5adj, 5adk, 5adl, 5adm, 5adn, 4uh7, 4uh8, 4uh9, 4uha, 4d33, 4d34, 4d35, 4d36, 4d37, 4d38, 4d39, 4d3a, 4cul, 4cum, 4cun, 4cvg, 4cwv, 4cww, 4cwx, 4cwy, 4cty, 4ctz, 4cu0, 4cu1 – b-eNOS OD+inhibitor
    
  • 4cwz, 4cx0, 4cx1, 4cx2 – b-eNOS OD (mutant) +inhibitor
    
  • 1d0c, 8nse, 1foj, 1ed5, 1d0o, 1d1w – b-eNOS OD+indazole derivative
    
  • 1dm8 – b-eNOS OD+triazole derivative
    
  • 1ed6 – b-eNOS OD+NO
    
  • 1q2o – b-eNOS OD (mutant)+dipeptide inhibitor
    
  • 1p6l, 1p6m – r-eNOS OD +dipeptide inhibitor - rat
    
  • 3nli - r-eNOS OD (mutant)+pyrrolidinomethyl aminopyridine derivative
    
  • 4jsk, 4jsl, 4jsm, 4imx, 4k5h, 4k5i, 4k5j, 4k5k, 4c3a – r-eNOS OD+ pyridine derivative
    
  • 4kcp, 4kcq, 4kcr, 4kcs - r-eNOS OD heme domain +thiophene carboximidamide derivative
    
• Neuronal NOS
  • 4uh5, 6av5, 6av4, 6av3 - h-nNOS heme domain +inhibitor
    
  • 4uh6, 4uch, 6av2, 6av1, 6av0, 6auz, 6auy, 5vv4, 5vv2, 5vv1, 5vuz, 5vuy, 5vux, 5vuw, 5vuv, 6nhb, 6nhc, 6cid, 6ng8, 6ngi, 6ngh, 6ngf, 6nge, 6ngd, 6ngc, 6ngb, 6nga, 6ng7, 6ng6, 6ng5, 6ng4, 6ng2, 6ng1, 6cic - h-nNOS heme domain + inhibitor
    
  • 4d1n - h-nNOS heme domain (mutant) + arginine
    
  • 2hx2 – b-nNOS OD+nitroguanidine derivative
    
  • 3nlv, 3nlw, 3nlx, 3nly, 3nlz, 3nm0, 4uh7, 4uh8, 4uh9, 4uha - b-nNOS OD + inhibitor
    
  • 3nli, 3nlj, 3nlk, 3nln, 3nlo, 3nlp, 3nlq, 3nlr, 3jws, 3jwt, 3jwu, 3jwv, 3jx0, 3jx1, 3jx2, 3jx3, 3jx4, 3jx5, 3jx6, 3pne, 3pnf, 3png, 3svp, 3svq - r-nNOS OD (mutant)+ pyridine derivative – rat
    
  • 3nlm, 3nny, 3nnz, 3n2r, 3b3o, 3b3p, 3b3m, 3b3n, 3rqj, 3rqk, 3rql, 3rqm, 3rqn, 3tyl, 3tym, 3tyn, 3tyo, 4ims, 4imt, 4imu, 4imw, 4jse, 4jsf, 4jsg, 4jsh, 4jsi, 4jsj, 4k5d, 4k5e, 4k5f, 4k5g, 4lux - r-nNOS OD+ pyridine derivative
    
  • 4gqe – r-nNOS OD + norvaline derivative
    
  • 1om4, 1k2r, 1k2s, 1lzx, 2hx4, 1zvl, 1qw6, 4fvw, 4fvx, 4fvy, 4fvz, 4fw0 - r-nNOS OD+arginine derivative
    
  • 4cam, 4can, 4cao, 4cap, 4caq, 4car, 4cdt, 4cft – r-nNOS OD heme domain + quinoline derivative
    
  • 1k2t, 1k2u – r-nNOS OD+thiourea derivative
    
  • 1om5 – r-nNOS OD+indazole derivative
    
  • 1lzz, 1m00, 2hx3– r-nNOS OD+guanidine derivative
    
  • 4kch, 4kci, 4kcj, 4kck, 4kcl, 4kcm, 4kcn, 4kco - r-nNOS OD heme domain +thiophene carboximidamide derivative
    
  • 3fc5, 1zvi – r-nNOS OD
    
  • 1qau - r-nNOS OD PDZ domain
    
  • 1qav, 4hop - r-nNOS OD PDZ domain + α-1 syntrophin
    
  • 1qwc, 3q99, 3q9a, 1mmv, 1mmw, 3dqr, 3ufo, 3ufp, 3ufq, 3ufr, 3ufs, 3uft, 3ufu, 3ufv, 3ufw, 4eux, 5vui, 4upm, 4upn, 4upo, 4upp, 5vuk, 5vul, 5vum, 5vun, 5vuo, 5vup, 5vuq, 5vur, 5vus, 5vut, 5vuu, 5unr, 5unt, 5unu, 5unv, 5unw, 5unx, 5uny, 5unz, 5uo0, 5fw0, 5fvo, 5fvp, 5fvq, 5fvr, 5fvs, 5fvt, 5agk, 5agl, 5agm, 5agn, 5ago, 5agp, 4v3v, 4v3w, 4v3x, 4v3y, 4v3z, 5ad4, 5ad5, 5ad6, 5ad7, 5ad8, 5ad9, 5ada, 5adb, 5adc, 4ugz, 4d33, 4d34, 4d35, 4d2y, 4d1z, 4d30, 4d31, 4uh4, 4d7o, 4d3b, 4d32, 4ctp, 4ctq, 4ctr, 4ctt, 4ctu, 4ctv, 4c39, 6aux, 6auw, 6auv, 6auu, 6aut, 6aur, 6auq, 5vuj, 4uh3, 4uh2, 4uh1, 4uh0, 4d2z, 4ctx, 4ctw, 6nhe, 6nhd, 6nh0, 6ngz, 6ngy, 6ngx, 6ngw, 6ngv, 6ngu, 6ngt, 6ngs, 6ngr, 6ngq, 6ngp, 6ngn, 6ngm, 6ngl, 6ngk, 6ngj – r-nNOS OD+inhibitor
    
  • 5vv0, 5vv3, 5vv5, 5uns, 5uo1, 5uo2, 5uo3, 5uo4, 5uo5, 5uo6, 5uo7, 5g0n, 5g0p, 5fvu, 5fvv, 5fvx, 5fvw, 5fvx, 4v3u, 5add, 5ade, 5adf, 5adg, 5adi, 4cx3, 4cx4, 4cx5, 4cx6, 6aus, 5g0o – r-nNOS OD (mutant) +inhibitor
    
  • 3jt3, 3jt4, 3jt5, 3jt6, 3jt7, 3jt8, 3jt9, 3jta – r-nNOS OD+ornithine derivative
    
  • 3hsn – r-nNOS OD+NHA+CO
    
  • 3hso, 3hsp - r-nNOS OD+NHA+NO
    
  • 2g6h, 2g6i, 2g6j – r-nNOS OD+pterin derivative
    
  • 2g6k, 2g6l – r-nNOS OD+pterin derivative+NO
    
  • 2g6m, 2g6n, 2g6o – r-nNOS OD+pterin derivative+CO
    
  • 1zzq, 1zzr, 1zzs, 1zzt, 1zzu, 1p6k – r-nNOS OD (mutant)+dipeptide inhibitor
    
  • 1rs6, 1rs7, 1p6h, 1p6i, 1p6j – r-nNOS OD +dipeptide inhibitor
    
  • 1b8q – r-nNOS PDZ domain + heptapeptide
    
  • 1f20 - r-nNOS FAD/NADP domain
    
  • 1vag – m-nNOS OD+inhibitor - mouse
    
• Inducible NOS

• • 3hr4 – h-iNOS residues 503-715+calmodulin
    
  • 3e7g – h-iNOS residues 82-505+inhibitor
    
  • 3ej8 – h-iNOS OD+imidazole
    
  • 4nos, 4cx7 – h-iNOS OD+inhibitor
    
  • 1nsi – h-iNOS OD+arginine
    
  • 2nsi – h-iNOS OD+thiourea derivative
    
  • 3nqs, 3e65, 3eai, 3ebd, 3ebf, 1r35, 2nod – m-iNOS OD + pterin derivative
    
  • 1jwj, 1jwk – m-iNOS OD (mutant)+ pterin derivative
    
  • 4ux6 – m-iNOS OD + pterin derivative + inhibitor
    
  • 2bhj – m-iNOS OD+coumarin
    
  • 3nod – m-iNOS OD+product analog
    
  • 1noc – m-iNOS OD+chloramphenicol acetyltransferase
    
  • 3e67 – m-iNOS OD+4-MAP
    
  • 3e68, 3e6l, 3e6n, 3e6o, 3e6t, 3e7i, 3e7m, 3e7t, 1vaf, 1qw5, 1dd7, 2y37 – m-iNOS OD+inhibitor
    
  • 2orq, 2orr, 2ors, 2ort, 2oro, 2orp, 1nos, 3nw2 – m-iNOS OD+imidazole derivative
    
  • 1df1 - m-iNOS OD+ urea derivative
    
  • 3dwj – m-iNOS OD (mutant)
    
  • 1qom, 4js9 - m-iNOS OD
    
  • 1qw4, 1dwv, 1dww, 1dwx, 1nod – m-iNOS OD+arginine derivative
    
  • 2nos – m-iNOS OD+guanidine derivative
    
  • 1n2n – m-iNOS OD+CN
    
  • 1m9t – m-iNOS OD+indazole derivative
    
  • 1m8d – m-iNOS OD+chlorzoxazone
    
  • 1m8e, 1m8h, 1m8i, 1m9m, 1m9q – m-iNOS OD+ indazole derivative
    
  • 1jwj – m-iNOS OD + inhibitor
    
  • 1jwk - m-iNOS OD (mutant) + inhibitor
    
  • 3gof - c-iNOS OD + calmodulin – chicken
    
• Prokaryote NOS
  • 2amo – BsNOS – Bacillus subtilis
    
  • 2an0, 2an2 – BsNOS (mutant)
    
  • 2fbz, 2fc2, 2fc1 – BsNOS+NO
    
  • 1m7v, 1m7z – BsNOS+THF+arginine
    
  • 5g67, 5g6q, 5g6p, 5g6o, 5g6n, 5g6m, 5g6l, 5g6k, 5g6j, 5g6i, 5g6h, 5g6g, 5g6f, 5g6e, 5g6d, 5g6c, 5g6b, 5g6a, 5g69, 5g68, 5g66, 5g65, 4ugl, 4uqs, 4uqr, 4ugy, 4ugx, 4ugw, 4ugv, 4ugu, 4ugt, 4ugs, 4ugr, 4ugq, 4ugp, 4ugo, 4ugn, 4ugm, 4ugk, 4ugj, 4ugi, 4ugh, 4ugg, 4ugf, 4uge, 4ugd, 4ugc, 4ugb, 4uga, 4ug9, 4ug8, 4ug7, 4ug6, 4ug5, 4lwb, 4lwa, 4d7j, 4d7i, 4d7h, 4d3v, 4d3u, 4d3t, 4d3o, 4d3n, 4d3m, 4d3k, 4d3j, 4d3i – BsNOS (mutant) + inhibitor
    
  • 2flq – NOS+arginine – Geobacillus stearothermophilus
    

Proteopedia Page Contributors and Editors (what is this?)

Sara Toftegaard Petersen, Jaime Prilusky, Alexander Berchansky, Mathilde Thomsen, Mette Trauelsen, Eran Hodis, Ann Taylor, Karl Oberholser, Michael Skovbo Windahl, Michal Harel